{"id":32994,"date":"2025-05-08T11:48:38","date_gmt":"2025-05-08T03:48:38","guid":{"rendered":"https:\/\/flcube.com\/?p=32994"},"modified":"2025-05-08T11:48:38","modified_gmt":"2025-05-08T03:48:38","slug":"grand-pharma-receives-nmpa-review-for-phase-iii-trial-of-tlx591-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32994","title":{"rendered":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer"},"content":{"rendered":"\n<p>China-based Grand Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG: 0512<\/a>) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).<\/p>\n\n\n\n<p><strong>Study Design<\/strong><br>The Phase III clinical study is designed as a prospective, randomized, controlled, open-label, global multi-center trial, expected to enroll over 500 patients across China, the US, Australia, and New Zealand. The trial will assess the benefits of TLX591 in combination with standard therapy compared to standard therapy alone.<\/p>\n\n\n\n<p><strong>TLX591 Overview<\/strong><br>TLX591 is an RDC carrying therapeutic radioactive isotopes, developed to treat prostate-specific membrane antigen (PSMA) positive mCRPC patients whose disease has progressed after ARPI treatment. The drug requires a dual-dose regimen with an interval of approximately 14 days, significantly shortening the treatment period and improving patient compliance.<\/p>\n\n\n\n<p><strong>Diagnostic Product and Collaboration<\/strong><br>TLX591-CDx, a related RDC product for diagnosing prostate cancer, initiated its Phase III clinical study in China in August 2023. Both TLX591 and TLX591-CDx are co-developed by Grand Pharma and its Australian partner Telix Pharmaceuticals Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/TLX:ASX\">ASX: TLX<\/a>).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050701871_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025050701871_c.\"><\/object><a id=\"wp-block-file--media-c7ed4c4e-d475-4078-b10a-fe04f84d7798\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050701871_c.pdf\">2025050701871_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050701871_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c7ed4c4e-d475-4078-b10a-fe04f84d7798\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,2403,17,683,1184,2402],"class_list":["post-32994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-asx-tlx","tag-clinical-trial-results","tag-grand-pharmaceutical","tag-hkg-0512","tag-telix-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T03:48:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer\",\"datePublished\":\"2025-05-08T03:48:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0801.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"ASX: TLX\",\"Clinical trial results\",\"Grand Pharmaceutical\",\"HKG: 0512\",\"Telix Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32994#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32994\",\"name\":\"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0801.webp\",\"datePublished\":\"2025-05-08T03:48:38+00:00\",\"description\":\"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32994\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32994","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer","og_description":"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).","og_url":"https:\/\/flcube.com\/?p=32994","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-08T03:48:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer","datePublished":"2025-05-08T03:48:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32994"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","keywords":["ADC \/ XDC","ASX: TLX","Clinical trial results","Grand Pharmaceutical","HKG: 0512","Telix Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32994#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32994","url":"https:\/\/flcube.com\/?p=32994","name":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32994#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","datePublished":"2025-05-08T03:48:38+00:00","description":"China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase III clinical study for its radionuclide drug conjugate (RDC) TLX591 (177Lu-HuJ591) has been accepted for review by the National Medical Products Administration (NMPA). The study aims to evaluate the efficacy and safety of TLX591 in combination with standard therapy compared to standard therapy alone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32994"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32994#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","width":1080,"height":608,"caption":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32994\/revisions"}],"predecessor-version":[{"id":32997,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32994\/revisions\/32997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32996"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}